Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
252.86
-5.52 (-2.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharmaceuticals plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
↗
October 04, 2024
Via
Benzinga
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
↗
September 19, 2024
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them.
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
↗
September 19, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
↗
September 09, 2024
Via
Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
↗
August 29, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
↗
August 28, 2024
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...
Via
Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
↗
August 19, 2024
Via
Benzinga
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
↗
August 01, 2024
Via
Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
↗
July 15, 2024
Via
Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
↗
August 27, 2024
Via
Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
↗
August 23, 2024
Via
Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
↗
August 08, 2024
Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
The 3 Best Cannabis Stocks to Buy in August 2024
↗
August 05, 2024
Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again.
Via
InvestorPlace
Topics
Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
↗
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
Via
InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
↗
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment.
Via
Investor's Business Daily
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
↗
July 02, 2024
Via
Benzinga
Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
↗
June 05, 2024
Via
Benzinga
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
↗
July 19, 2024
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.
Via
InvestorPlace
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
↗
July 11, 2024
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical...
Via
Benzinga
Topics
Cannabis
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
↗
July 11, 2024
Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company...
Via
Benzinga
Topics
Cannabis
3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
↗
July 04, 2024
Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks
Via
InvestorPlace
7 Biotech Stocks to Boost Your Portfolio to Peak Health
↗
June 26, 2024
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
Via
InvestorPlace
3 Cannabis Stocks That Could Make Your Grandchildren Rich
↗
June 25, 2024
These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today.
Via
InvestorPlace
Topics
Cannabis
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
↗
June 20, 2024
Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.
Via
Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
↗
June 20, 2024
The companies are working on treatments for essential tremor, a tricky indication.
Via
Investor's Business Daily
3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
↗
June 14, 2024
These blue-chip stocks offer stability, sustainable growth and operational models less prone to wider economic fluctuations.
Via
InvestorPlace
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
June 05, 2024
Via
Benzinga
7 Overlooked Stocks Offering Long-Term Stability From the Shadows
↗
June 03, 2024
These overlooked stocks offer price appreciation, income, and more while diversifying across sectors and company sizes.
Via
InvestorPlace
3 Cannabis Stocks to Buy Now: May 2024
↗
May 26, 2024
These cannabis stocks to buy offer the best odds at capturing long-term upside from current rescheduling initiatives.
Via
InvestorPlace
Topics
Cannabis
7 Blue-Chip Stocks to Buy Now: May 2024
↗
May 23, 2024
These blue-chip stocks to buy offer long-term price appreciation opportunities reinforced with undeniable stock stability.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.